Noncanonical HLA-I tumour ligand immunogenicity
downstream-application
Noncanonical HLA-I tumour ligand immunogenicity: downstream-application. A de novo sequencing-based proteogenomic search found noncanonical HLA-I ligands in nine patient tumour cell lines; none was recognized by autologous T cells, though…
A de novo sequencing-based proteogenomic search found noncanonical HLA-I ligands in nine patient tumour cell lines; none was recognized by autologous T cells, though some elicited TCRs from donor blood.
| Kind | downstream-application |
| Deep learning | no |
| Acquisition | DDA |
| Application area | Immunopeptidomics / neoantigen |
Paper describing it
- Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics (2023, Clinical Cancer Research, peer-reviewed)